Obesity Today—May 26, 2026

This week’s Obesity update highlights regulatory progress, late-stage clinical wins, emerging oral therapies, and expanding metabolic disease pipelines.

In this Newsletter

Dive deeper

💊 VCT220 oral GLP-1RA Phase 3 obesity win [1] [China • 19 May 2026]

https://www.clinicaltrialsarena.com/news/vincentage-pharma-touts-phase-iii-win-for-oral-glp-1ra/
Context: Vincentage Pharma tested VCT220 in a China Phase 3 obesity trial, NCT06939296, enrolling 840 adults with obesity or overweight plus comorbidity.
Key point: VCT220 achieved 12.2% and 12.4% mean body-weight reduction at 52 weeks across two doses versus 1.3% with placebo.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Lilly retatrutide clears TRIUMPH-1 obesity trial [2] [US • 21 May 2026]

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
Context: Eli Lilly evaluated retatrutide, a GIP, GLP-1, and glucagon triple receptor agonist, in adults with obesity or overweight without diabetes.
Key point: Retatrutide met primary and key secondary endpoints in TRIUMPH-1, with 25.9% and 28.3% mean weight loss at 80 weeks for 9 mg and 12 mg.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Verdiva Bio oral obesity candidates head to ADA 2026 [3] [US • 20 May 2026]

https://www.businesswire.com/news/home/20260519669196/en/Verdiva-Bio-to-Present-Preclinical-Data-on-Investigational-Obesity-Drug-Candidates-at-the-American-Diabetes-Association-86th-Scientific-Sessions
Context: Verdiva Bio will present preclinical data at ADA 2026 for VRB-103 and VRB-104 in New Orleans on 07 Jun 2026.
Key point: VRB-103 is a once-weekly oral amylin analog, while VRB-104 is a unimolecular GLP-1 plus amylin co-agonist.
Implication: Signals pipeline investment and modality expansion.

🇰🇷 Korean GLP-1-linked MASH candidates head to EASL 2026 [4] [EU • 21 May 2026]

https://www.asiae.co.kr/en/article/2026052108072492515
Context: D&D Pharmatech, Dong-A ST, and Yuhan Corporation will present MASH and obesity-related data at EASL 2026 in Barcelona.
Key point: DD01, DA-1726, and YH25724 use different GLP-1-linked mechanisms across MASH, obesity, and liver-fat reduction programs.
Implication: Signals pipeline investment and modality expansion.

📈 CNBC frames retatrutide as Lilly’s next obesity-market pillar [5] [US • 21 May 2026]

https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html
Context: CNBC reported Lilly’s TRIUMPH-1 results and analyst expectations for retatrutide in the obesity market.
Key point: The highest retatrutide dose produced 28.3% mean weight loss at 80 weeks in completers, while about 45% achieved at least 30% weight loss.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Oral and injectable obesity assets continue to fragment by modality, mechanism, dosing, and tolerability profile.
Retatrutide strengthens Lilly’s next-generation obesity position beyond Zepbound and Foundayo.
VCT220 adds China-based oral GLP-1RA competition, with a planned NMPA submission.
Amylin and GLP-1 plus amylin combinations are moving into broader obesity pipeline visibility.
Korean biotechs are positioning differentiated GLP-1-linked mechanisms in MASH, a field still seeking clearer efficacy and fibrosis signals.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Obesity archive on our research hub page

🎯 Catch up on the Top Obesity news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is VCT220 from Vincentage Pharma?

VCT220 is an oral GLP-1 receptor agonist for weight management. In a China Phase 3 obesity trial, it met primary endpoints and showed 12.2% to 12.4% mean weight loss at 52 weeks [1].

What is retatrutide from Eli Lilly?

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. In TRIUMPH-1, Lilly reported clinically meaningful weight loss across all tested doses [2].

How did retatrutide perform at the highest dose?

Lilly reported 28.3% mean weight loss at 80 weeks for the 12 mg dose in the efficacy estimand. CNBC reported the same figure for patients who stayed on treatment [2], [5].

What is Verdiva Bio presenting at ADA 2026?

Verdiva Bio will present preclinical data for VRB-103, an oral amylin analog, and VRB-104, a GLP-1 plus amylin co-agonist. Both are investigational obesity candidates [3].

Which Korean companies are presenting MASH data at EASL 2026?

D&D Pharmatech, Dong-A ST, and Yuhan Corporation are presenting candidates DD01, DA-1726, and YH25724. The programs use different GLP-1-linked or liver-directed mechanisms [4].

Entities / Keywords

Vincentage Pharma, VCT220, CX11, oral GLP-1RA, GLP-1 receptor agonist, obesity, NMPA
Eli Lilly, retatrutide, TRIUMPH-1, GIP, GLP-1, glucagon, triple agonist, Zepbound, Foundayo
Verdiva Bio, VRB-103, VRB-104, amylin analog, GLP-1 plus amylin co-agonist, ADA 2026
D&D Pharmatech, DD01, GLP-1 plus glucagon dual agonist, MASH
Dong-A ST, Metavia, DA-1726, oxyntomodulin analog, obesity, MASH
Yuhan Corporation, YH25724, GLP-1 plus FGF21 dual agonist
EASL 2026, ADA 2026, obesity pharmacotherapy, metabolic disease